US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Amicus Therapeutics, Inc. - Common Stock
(NQ:
FOLD
)
14.49
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amicus Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
February 20, 2026
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders
February 19, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
February 03, 2026
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations
February 02, 2026
Shareholders should contact the firm as there may be limited time to enforce your rights
From
Halper Sadeh LLC
Via
GlobeNewswire
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
January 23, 2026
From
Halper Sadeh LLC
Via
Business Wire
Halper Sadeh LLC Encourages PEN, FOLD, DBRG, FFIC Shareholders to Contact the Firm to Discuss Their Rights
January 22, 2026
Shareholders should contact the firm as there may be limited time to enforce your rights
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights
January 07, 2026
Shareholders should contact the firm as there may be limited time to enforce your rights
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights
January 06, 2026
Shareholders should contact the firm as there may be limited time to enforce your rights.
From
Halper Sadeh LLC
Via
GlobeNewswire
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
December 26, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq
December 23, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights
December 20, 2025
Shareholders should contact the firm as there may be limited time to enforce your rights.
From
Halper Sadeh LLC
Via
GlobeNewswire
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
December 19, 2025
From
Halper Sadeh LLC
Via
Business Wire
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
December 04, 2025
Via
Investor Brand Network
Topics
Government
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
November 04, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
December 04, 2025
From
BioMedWire
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
October 31, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
October 23, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
September 08, 2025
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda®
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
August 29, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
August 06, 2025
Via
Investor Brand Network
Topics
Government
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
August 06, 2025
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Government
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
July 31, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
July 21, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
June 25, 2025
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD)
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
June 03, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
May 30, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
May 07, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
May 01, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
April 30, 2025
From
Amicus Therapeutics, Inc.; Dimerix Limited
Via
GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
April 21, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
